There is no single best next-generation sequencing platform—only the best match for a defined experiment. The central trade-off in the field is straightforward: short-read instruments such as the Illumina NovaSeq 6000 and MGI DNBSEQ-T7 deliver high accuracy and low cost per base, while long-read systems from PacBio and Oxford Nanopore stretch reads from hundreds of bases to tens of thousands, unlocking regions short reads cannot resolve. Here is how the evidence stacks up when choosing between them.
Understanding Next-Generation Sequencing Technologies
Next-generation sequencing has reshaped genomics by enabling comprehensive genome sequencing alongside transcriptomics, epigenomics, metagenomics and other omics studies, according to a review of current trends in the technology. Its high-throughput capacity and cost-effectiveness have made it a fundamental tool across disciplines ranging from basic biology to clinical diagnostics.
The platforms divide into two broad families. Short-read sequencers produce reads of roughly 600–700 bases at most; long-read, third-generation platforms can generate reads up to 25–30 kilobases, a review of NGS technology reports. That order-of-magnitude difference in read length is not a marginal specification—it determines which questions each instrument can actually answer.
A further distinction sits in library preparation. Long-read workflows can be PCR-free, which removes amplification bias. As the review puts it, "the base modification such as DNA methylation can be easily detected by long-read sequencing"—a capability PCR-amplified short-read workflows do not offer as directly. The same review notes that newer high-throughput platforms have significantly reduced error rates and improved long-read accuracy, narrowing what was once the technology's main weakness.
